TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™Business Wire • Wednesday
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock UpZacks Investment Research • 11/10/26
TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/09/26
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceBusiness Wire • 11/09/26
Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep CorrectionSeeking Alpha • 11/09/26
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business UpdateBusiness Wire • 11/02/26
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/26/26
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026Business Wire • 10/23/26
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026Business Wire • 10/21/26
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple SclerosisBusiness Wire • 10/12/26
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/10/26